When comparing dutasteride with finasteride , no significant differences in symptom improvement or the rate of adverse events were observed .
Conclusions Dutasteride can be used to improve urinary symptoms ( IPSS and Qmax ) and reduce TPV but with awareness of its potential adverse events .
Purpose To determine the efficacy and safety of dutasteride , alone or in combination , versus a placebo or control , used for the treatment of benign prostatic hyperplasia .
Natural history of prostatism: risk factors for acute urinary retention.
PURPOSE We determined the occurrence of and risk factors for acute urinary retention in the community setting . MATERIAL S AND METHODS A cohort of 2,115 men 40 to 79 years old was r and omly selected from an enumeration of the Olmsted County , Minnesota population ( 55 % response rate ) . Participants completed a previously vali date d baseline question naire that assessed symptom severity , and voided into a portable urometer to measure peak urinary flow rates . A 25 % r and om sub sample underwent transrectal sonographic imaging of the prostate to determine prostate volume . Followup was performed through a retrospective review of community medical records to determine the occurrence of acute urinary retention in the subsequent 4 years . RESULTS During the 8,344 person-years of followup 57 men had a first episode of acute urinary retention ( incidence 6.8/1,000 person-years , 95 % confidence interval [ CI ] 5.2 , 8.9 ) . Among men with no to mild symptoms ( American Urological Association symptom index score 7 or less ) the incidence of acute urinary retention increased from 2.6/1,000 person-years among men 40 to 49 years old to 9.3/1,000 person-years among men 70 to 79 years old . By contrast , rates increased from 3.0/1,000 person-years for men 40 to 49 years old to 34.7/1,000 person-years among men 70 to 79 years old among men with moderate to severe symptoms ( American Urological Association symptom index score greater than 7 ) . Men with depressed peak urinary flow rate ( less than 12 ml . per second ) were at 4 times the risk of acute urinary retention compared with men with urinary flow rates greater than 12 ml . per second ( 95 % CI 2.3 , 6.6 ) . Men with an enlarged prostate ( greater than 30 ml . ) experienced a 3-fold increase in risk ( 95 % CI 1.0 , 9.0 , p = 0.04 ) . CONCLUSIONS Lower urinary tract symptoms , depressed peak urinary flow rates , enlarged prostates and older age are associated with an increased risk of acute urinary retention in community dwelling men . These findings may help to identify men at increased risk of acute urinary retention in whom closer evaluation may be warranted
When comparing dutasteride with finasteride , no significant differences in symptom improvement or the rate of adverse events were observed .
Conclusions Dutasteride can be used to improve urinary symptoms ( IPSS and Qmax ) and reduce TPV but with awareness of its potential adverse events .
Purpose To determine the efficacy and safety of dutasteride , alone or in combination , versus a placebo or control , used for the treatment of benign prostatic hyperplasia .